Skip to main content

Oramed Pharmaceuticals Inc. (ORMP)

NASDAQ: ORMP · IEX Real-Time Price · USD
20.21 1.29 (6.82%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap768.71M
Revenue (ttm)2.70M
Net Income (ttm)-22.24M
Shares Out38.04M
EPS (ttm)-0.71
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume663,744
Open27.25
Previous Close18.92
Day's Range18.36 - 20.50
52-Week Range2.50 - 31.54
Beta1.80
AnalystsStrong Buy
Price Target28.00 (+38.5%)
Earnings Daten/a

About ORMP

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a w...

IndustryPharmaceuticals
Founded2002
CEONadav Kidron
Employees12
Stock ExchangeNASDAQ
Ticker SymbolORMP
Full Company Profile

Financial Performance

In 2021, ORMP's revenue was $2.70 million, a decrease of -0.26% compared to the previous year's $2.71 million. Losses were -$22.24 million, 93.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ORMP stock is "Strong Buy." The 12-month stock price forecast is 28.00, which is an increase of 38.55% from the latest price.

Price Target
$28.00
(38.55% upside)
Analyst Consensus: Strong Buy

News

Oramed to Join MSCI USA Small Cap Index

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

3 days ago - PRNewsWire

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

NEW YORK, Nov. 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

4 days ago - PRNewsWire

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commerci...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its...

Other symbols:MYMD
1 week ago - Business Wire

Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Or...

NEW YORK and MEXICO CITY, Nov. 18, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of or...

1 week ago - PRNewsWire

Oramed to Present at H.C. Wainwright 7th Annual Israel Conference

NEW YORK, November 11, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deli...

2 weeks ago - PRNewsWire

Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq ...

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the develo...

2 weeks ago - PRNewsWire

Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

NEW YORK, Nov. 3, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the develo...

3 weeks ago - PRNewsWire

Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial

NEW YORK, Oct. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

4 weeks ago - PRNewsWire

7 Top-Rated Pharmaceutical Stocks To Invest in for October

It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared first ...

Other symbols:CLSDINVAMTEXUTHRVERU
1 month ago - InvestorPlace

Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delive...

2 months ago - PRNewsWire

Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

2 months ago - PRNewsWire

Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

2 months ago - PRNewsWire

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

3 months ago - PRNewsWire

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

3 months ago - PRNewsWire

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing...

Other symbols:MYMD
3 months ago - Business Wire

Oramed to Present at Canaccord Genuity's 41st Annual Growth Conference

NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

3 months ago - PRNewsWire

Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021

NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

3 months ago - PRNewsWire

Oramed Pharmaceuticals Appoints Chief Commercial Officer

NEW YORK, July 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

3 months ago - PRNewsWire

Oramed Will Soon Start Clinical Trials For Oral COVID-19 Vaccine In Israel, Out licensed Injectable Version To Premas...

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced several updates for its majority-owned company Oravax Medical Inc. Oravax is gearing up to commence clinical trials for its oral COVID-19 vaccine, fir...

4 months ago - Benzinga

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

NEW YORK, June 22, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

5 months ago - PRNewsWire

Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

NEW YORK, June 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

5 months ago - PRNewsWire

Oramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine

NEW YORK, May 25, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

6 months ago - PRNewsWire

Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners' Grand Rounds: A Webinar in Biot...

NEW YORK, April 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

7 months ago - PRNewsWire

Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA's Approved Dual Concurrent Protocol

NEW YORK, March 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

8 months ago - PRNewsWire

Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose

GURUGRAM, India--(BUSINESS WIRE)-- #Antibodies--Premas Biotech and Oramed announce Oral COVID-19 vaccine candidate that produces Antibodies after a single dose.

8 months ago - Business Wire